Moderna (NASDAQ:MRNA) Shares Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

Moderna Trading Up 2.2 %

NASDAQ:MRNA traded up $0.59 during mid-day trading on Wednesday, hitting $27.75. The stock had a trading volume of 7,785,632 shares, compared to its average volume of 11,580,042. Moderna, Inc. has a twelve month low of $26.26 and a twelve month high of $170.47. The stock has a 50-day simple moving average of $34.43 and a two-hundred day simple moving average of $43.55. The company has a market capitalization of $10.73 billion, a PE ratio of -2.99 and a beta of 1.86.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on MRNA shares. Berenberg Bank raised their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a report on Thursday, January 16th. Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research report on Tuesday, February 11th. Morgan Stanley cut their target price on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Wednesday, January 15th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average price target of $59.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC grew its position in Moderna by 60.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 13,431 shares of the company's stock valued at $558,000 after buying an additional 5,078 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in shares of Moderna in the 4th quarter worth $4,486,000. PKO Investment Management Joint Stock Co acquired a new stake in shares of Moderna in the 4th quarter worth $249,000. Probity Advisors Inc. boosted its holdings in shares of Moderna by 121.8% in the fourth quarter. Probity Advisors Inc. now owns 10,746 shares of the company's stock valued at $447,000 after acquiring an additional 5,902 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Moderna during the fourth quarter worth about $18,084,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.